Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz's continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia.

PRNewsWire • Jun 4, 2026

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 3, 2026

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 1, 2026

Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Transcript

Seeking Alpha • May 27, 2026

Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line setting Additional subgroup analyses to be presented at the 2026 ASCO Annual Meeting show improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients For U.S. media and investors only   DUBLIN, May 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safety profile of Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with and without the PD-1 inhibitor Tevimbra® (tislelizumab), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. The manuscript builds on the late-breaking oral presentation of the HERIZON-GEA-01 trial results at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI), where zanidatamab-containing combinations demonstrated unprecedented progression-free survival (PFS) and overall survival (OS) outcomes in a global Phase 3 trial.

PRNewsWire • May 27, 2026

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 26, 2026

UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point

One of Wall Street's major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying.

24/7 Wall Street • May 19, 2026

Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 19, 2026

Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?

JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.

Zacks Investment Research • May 13, 2026